Now, the companies that make GLP-1s are driving innovation in systems to make medications affordable.
The explosive rise of GLP-1 medications—such as Mounjaro, Ozempic, and Wegovy—has ignited more than just headlines. It has fundamentally shifted how Americans access and pay for medications, driving innovation in affordability models, and fueling a dramatic increase in direct-to-consumer (DTC) healthcare platforms.
